18 recruiting, 8 completed, 7 active not recruiting, 3 unknown. 28 Phase 2, 20 Phase 1, 8 Phase 3.
Follow Lurbinectedin: new trials by email Literature Review of Lurbinectedin trials Research Report on Lurbinectedin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer Lurbinectedin, Osimertinib - Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Misty Shields | 16 | 2027-01-01 | 2026-10-15 |
| A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC Lurbinectedin, Durvalumab - Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Jazz Pharmaceuticals | 50 | 2026-11-30 | 2026-09-17 |
| Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer Lurbinectedin, Paclitaxel - Carcinoma, Small Cell Lung | Phase 2 | Not yet recruiting | Yonsei University | 69 | 2026-11-01 | 2026-09-04 |
| BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin - Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer | Phase 3 | Recruiting | SystImmune Inc. | 550 | 2026-08-04 | 2026-10-15 |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer ABBV-706, Topotecan, Lurbinectedin - Small Cell Lung Cancer | Phase 3 | Recruiting | AbbVie | 531 | 2026-07-02 | 2026-09-23 |
| Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC Stenoparib/Temozolomide, Lurbinectedin - Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | VA Office of Research and Development | 166 | 2026-02-23 | 2026-03-11 |
| An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing Serplulimab, Fluzoparib, Topotecan/Irinotecan/Paclitaxel/Temozolomide - SCLC, Extensive Stage | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 100 | 2025-12-31 | 2025-08-26 |
| An Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment Lurbinectedin, Radiation Therapy - Small Cell Lung Carcinoma | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 9 | 2025-12-31 | 2026-06-16 |
| A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer ABBV-706, Atezolizumab, Etoposide - Small Cell Lung Cancer | Phase 2 | Recruiting | AbbVie | 180 | 2025-11-25 | 2026-10-27 |
| Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS Lurbinectedin, Irinotecan - Desmoplastic Small Round Cell Tumor | Phase 2 | Recruiting | Italian Sarcoma Group | 20 | 2025-11-21 | 2026-11-03 |
| Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC Serplulimab, Lurbinectedin, Carboplatin - Extensive-Stage Small Cell Lung Cancer | Phase 2 | Recruiting | Guangzhou Institute of Respiratory Disease | 30 | 2024-12-01 | 2026-06-08 |
| Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas Lurbinectedin, Radiotherapy, Non-investigational surgery - Locally Advanced Soft Tissue Sarcoma | Phase 1 / Phase 2 | Withdrawn | University of California, San Francisco | 2024-10-31 | 2024-11-18 | |
| Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC Lurbinectedin, Irinotecan, Topotecan - Relapsed Small Cell Lung Cancer | Phase 3 | Recruiting | Luye Pharma Group Ltd. | 180 | 2024-09-14 | 2024-12-12 |
| Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) Lurbinectedin, Avelumab - Small Cell Carcinoma of the Bladder, High Grade Neuroendocrine Tumors of the Urinary Tract | Phase 2 | Recruiting | National Cancer Institute (NCI) | 45 | 2024-06-13 | 2026-10-16 |
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer Ifinatamab deruxtecan, Topotecan, Amrubicin - Small Cell Lung Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 540 | 2024-05-21 | 2026-08-06 |
| Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer Lurbinectedin, Dostarlimab - Endometrial Cancer | Phase 1 / Phase 2 | Withdrawn | Vall d'Hebron Institute of Oncology | 2024-05-01 | 2025-04-01 | |
| Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) Lurbinectedin, Doxorubicin - Leiomyosarcoma | Phase 3 | Active not recruiting | PharmaMar | 469 | 2023-09-21 | 2026-06-18 |
| A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel. - Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC) | Phase 1 / Phase 2 | Recruiting | Phanes Therapeutics | 203 | 2023-09-05 | 2026-07-15 |
| Lurbinectedin in FET-Fused Tumors Lurbinectedin - Ewing Sarcoma, Desmoplastic Small Round Cell Tumor | Phase 1 / Phase 2 | Recruiting | Children's Hospital of Philadelphia | 63 | 2023-07-27 | 2026-09-02 |
| Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer Paclitaxel, Bevacizumab, Lurbinectedin - Ovarian Cancer | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 34 | 2023-07-12 | 2026-08-20 |
Showing 20 of 44. Sign in to see all of them.
Small Cell Lung Carcinoma (24) · Lung Neoplasms (5) · Neoplasms (4) · Sarcoma (4) · Endometrial Neoplasms (3) · Sarcoma, Ewing (3) · Desmoplastic Small Round Cell Tumor (2) · Mesothelioma (2) · Ovarian Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Small Cell (1) · Colorectal Neoplasms (1)
Jazz Pharmaceuticals (5) · PharmaMar (5) · AbbVie (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · M.D. Anderson Cancer Center (2) · Massachusetts General Hospital (2) · National Cancer Institute (NCI) (2) · Amgen (1) · Antonio Calles Blanco (1) · Children's Hospital of Philadelphia (1) · Daiichi Sankyo (1) · ERLINDA M GORDON (1) · Emory University (1) · Fox Chase Cancer Center (1) · Guangzhou Institute of Respiratory Disease (1)
United States (29) · Spain (14) · Italy (10) · Germany (9) · France (8) · Belgium (7) · Poland (7) · Switzerland (7) · Canada (6) · China (6) · South Korea (6) · Austria (5) · Greece (5) · Hungary (5) · Japan (5)
Alberto A Chiappori, MD (1) · Anastasios Dimou, MD (1) · Andrea B Apolo, M.D. (1) · Andres Poveda, MD (1) · Anish Thomas, M.D. (1) · Antonio Calles (1) · Erlinda M Gordon, MD (1) · Federica Grosso, MD (1) · Gregory Cote, M.D. Ph.D (1) · Gregory Cote, MD PhD (1) · Hye Ryun Kim (1) · Jared Weiss, MD (1)
PMID 40963055, PMID 31896519, PMID 32085891, PMID 37491889, PMID 39530627, PMID 39932221, PMID 39938593, PMID 40116623, PMID 40473449, PMID 41055143, PMID 41791703, PMID 42081171, PMID 42377743
2023 (2), 2025 (2), 2017 (1), P30CA138292 (1)